Company Remains Committed to Infectious Diseases & Vaccines
MedImmune, the global biologics arm of AstraZeneca PLC, announced that it is restructuring its infectious disease and vaccines research, development and operations. This will result in the closure of MedImmune’s Mountain View, CA and Santa Clara, CA sites, and consolidation of its infectious disease and vaccines research and development activities to other existing sites. The changes are expected to be completed in 2014 to allow for a seamless transition of ongoing activities.
MedImmune’s Hayward, CA site will remain open with additional capabilities invested in the site.
MedImmune is committed to infectious diseases and vaccines research and development and believes that these changes will enhance innovation across its therapeutic areas and improve alignment with other areas of product development while reducing the fixed costs associated with the sites.
The company estimates that approximately 300 positions will be impacted. Of those, approximately 100 positions will move to other MedImmune locations, including its Hayward, CA site. The changes will not disrupt the delivery of our vaccine supply.
In February 2012, AstraZeneca announced an efficiency program to improve productivity, foster innovation and strengthen the company’s commercial, operations and R&D capabilities, which runs through 2014. These actions are part of MedImmune’s commitment to delivering that program. MedImmune continues to advance its pipeline with 120 biologics in research and development.
Leadership in Vaccine Development
MedImmune is recognized as a leader in vaccine development. In 2003, the U.S. Food and Drug Administration (FDA) approved FluMist® (Influenza Vaccine Live, Intranasal). The company also developed and received FDA approval in February 2012 for FluMist®Quadrivalent (Influenza Vaccine Live, Intranasal), the first-of-its-kind four strain vaccine.
MedImmune is committed to delivering innovative and effective treatments to patients with severe disabling diseases and unmet medical needs.
MedImmune, the global biologics arm for AstraZeneca PLC, has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune’s website at www.medimmune.com.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.